We are live on ! Find out more
NVCT icon

Nuvectis Pharma
NVCT

33 hedge funds and large institutions have $20M invested in Nuvectis Pharma in 2025 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 3 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

333% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 3

181% more capital invested

Capital invested by funds: $7.15M → $20M (+$12.9M)

45% more call options, than puts

Call options by funds: $1.3M | Put options by funds: $895K

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

6% more funds holding

Funds holding: 31 → 33 (+2)

1.92% more ownership

Funds ownership: 6.84% → 8.75% (+1.9%)

Holders
33
Holders Change
+2
Holders Change %
+6.45%
% of All Funds
0.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
13
Reduced
3
Closed
8
Calls
$1.3M
Puts
$895K
Net Calls
+$406K
Net Calls Change
+$406K

Top Buyers

Rank Fund Capital Flow
1
IAM
Iridian Asset Management
Connecticut
+$1.83M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.02M
3
UBS Group
UBS Group
Switzerland
+$784K
4
Millennium Management
Millennium Management
New York
+$658K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$404K

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$617K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$328K
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$166K
4
Squarepoint
Squarepoint
New York
-$58K
5
CSS
Cubist Systematic Strategies
Connecticut
-$34.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
JG
26
Jain Global
New York
$99.2K +$73.1K +10,154 New
Morgan Stanley
27
Morgan Stanley
New York
$68.2K +$33.5K +4,658 +201%
Bank of America
28
Bank of America
North Carolina
$16.2K +$295 +41 +3%
Barclays
29
Barclays
United Kingdom
$11.3K +$108 +15 +1%
Citigroup
30
Citigroup
New York
$10K +$7.38K +1,025 New
JP Morgan Chase
31
JP Morgan Chase
New York
$1.75K – – –
BNP Paribas Financial Markets
32
BNP Paribas Financial Markets
France
$997 -$94 -13 -11%
SPIA
33
Steward Partners Investment Advisory
New York
$977 – – –
Susquehanna International Group
34
Susquehanna International Group
Pennsylvania
– -$328K -45,607 Closed
Qube Research & Technologies (QRT)
35
Qube Research & Technologies (QRT)
United Kingdom
– -$166K -30,594 Closed
CSS
36
Cubist Systematic Strategies
Connecticut
– -$34.1K -6,294 Closed
PAS
37
Point72 Asia (Singapore)
Singapore
– -$24.2K -4,479 Closed
HCM
38
Hollencrest Capital Management
California
– -$2.16K -400 Closed
RS
39
R Squared
Hong Kong
– -$1.68K -310 Closed
PD
40
Point72 (DIFC)
United Arab Emirates
– -$265 -49 Closed
NS
41
NBC Securities
Alabama
– -$27 -5 Closed
1
2

NVCT Hedge Fund Activity: Q1 2025 in Review

33 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q1 2025, worth a combined $20M — up 181% from $7.15M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new NVCT positions and 8 closed out — a net gain of 2 holders — while 13 added to existing stakes and 3 trimmed.

The largest buyer was Iridian Asset Management, opening a new position worth an estimated $1.83M. The largest seller was Marshall Wace, cutting an estimated $617K.

  • 33 institutional investors held Nuvectis Pharma (NVCT) as of Q1 2025, up from 31 in Q4 2024.
  • Funds reported $20M of Nuvectis Pharma stock for Q1 2025, up 181% quarter-over-quarter.
  • 10 funds opened new Nuvectis Pharma positions in Q1 2025 and 8 closed out, a net change of +2 holders.
  • The largest Nuvectis Pharma buyer in Q1 2025 was Iridian Asset Management, an estimated $1.83M added.
  • The largest Nuvectis Pharma seller in Q1 2025 was Marshall Wace, an estimated $617K sold.

Based on aggregated 13F filings for Q1 2025.